Comparative Pharmacology
Head-to-head clinical analysis: LYBALVI versus RISVAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LYBALVI versus RISVAN.
LYBALVI vs RISVAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LYBALVI is a combination of olanzapine and samidorphan. Olanzapine is an atypical antipsychotic with high affinity for serotonin 5-HT2A and 5-HT2C, dopamine D1-D4, histamine H1, and alpha1-adrenergic receptors. Samidorphan is an opioid receptor antagonist with high affinity for mu-opioid receptors, hypothesized to reduce olanzapine-associated weight gain by blocking opioid receptors in the central nervous system.
Risperidone is an atypical antipsychotic that acts as a serotonin 5-HT2A and dopamine D2 receptor antagonist. It also binds to alpha1-adrenergic and H1 histaminergic receptors.
Olanzapine 10 mg / samidorphan 10 mg orally once daily.
70 mg orally once daily, with or without food.
None Documented
None Documented
Terminal half-life ~20-30 hours; supports once-daily dosing.
Terminal elimination half-life: 12-15 hours in healthy adults; prolonged to 20-30 hours in hepatic impairment (Child-Pugh B/C).
Renal: ~50% as unchanged drug and metabolites; Fecal: ~40%; Biliary: minor.
Renal: 30% unchanged; Fecal: 65% (biliary excretion of metabolites); 5% other.
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic